MK-6018
Biological
Merck Sharp & Dohme Corporation
Total Payments
$55,135
Transactions
12
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $30,411 | 9 | 0 |
| 2017 | $24,724 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54,485 | 11 | 98.8% |
| Consulting Fee | $650.00 | 1 | 1.2% |
Payments by Type
Research
$54,485
11 transactions
General
$650.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I, Open-Label, Multicenter, Multi-Dose Escalcation Study of MK-6018 CM-24 with or without Pembrolizmuab in Subjects with Selected Advanced or Recurrent Malignancies | Merck Sharp & Dohme Corporation | $54,485 | 0 |
Top Doctors Receiving Payments for MK-6018
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Haven, CT | $54,485 | 11 |
| , M.D | Medical Oncology | Boston, MA | $650.00 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $55,135
Product Information
- Type Biological
- Total Payments $55,135
- Total Doctors 1
- Transactions 12
About MK-6018
MK-6018 is a biological associated with $55,135 in payments to 1 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $30,411 was paid across 9 transactions to 0 doctors.
The most common payment nature for MK-6018 is "Unspecified" ($54,485, 98.8% of total).
MK-6018 is associated with 1 research study, including "A Phase I, Open-Label, Multicenter, Multi-Dose Escalcation Study of MK-6018 CM-24 with or without Pembrolizmuab in Subjects with Selected Advanced or Recurrent Malignancies" ($54,485).